212 related articles for article (PubMed ID: 15107491)
1. The initiative role of XPC protein in cisplatin DNA damaging treatment-mediated cell cycle regulation.
Wang G; Chuang L; Zhang X; Colton S; Dombkowski A; Reiners J; Diakiw A; Xu XS
Nucleic Acids Res; 2004; 32(7):2231-40. PubMed ID: 15107491
[TBL] [Abstract][Full Text] [Related]
2. The involvement of XPC protein in the cisplatin DNA damaging treatment-mediated cellular response.
Wang G; Dombkowski A; Chuang L; Xu XX
Cell Res; 2004 Aug; 14(4):303-14. PubMed ID: 15353127
[TBL] [Abstract][Full Text] [Related]
3. Nucleotide excision repair factor XPC enhances DNA damage-induced apoptosis by downregulating the antiapoptotic short isoform of caspase-2.
Wang QE; Han C; Zhang B; Sabapathy K; Wani AA
Cancer Res; 2012 Feb; 72(3):666-75. PubMed ID: 22174370
[TBL] [Abstract][Full Text] [Related]
4. Defining the function of XPC protein in psoralen and cisplatin-mediated DNA repair and mutagenesis.
Chen Z; Xu XS; Yang J; Wang G
Carcinogenesis; 2003 Jun; 24(6):1111-21. PubMed ID: 12807748
[TBL] [Abstract][Full Text] [Related]
5. Malignant melanoma cells acquire resistance to DNA interstrand cross-linking chemotherapeutics by p53-triggered upregulation of DDB2/XPC-mediated DNA repair.
Barckhausen C; Roos WP; Naumann SC; Kaina B
Oncogene; 2014 Apr; 33(15):1964-74. PubMed ID: 23604128
[TBL] [Abstract][Full Text] [Related]
6. The involvement of ataxia-telangiectasia mutated protein activation in nucleotide excision repair-facilitated cell survival with cisplatin treatment.
Colton SL; Xu XS; Wang YA; Wang G
J Biol Chem; 2006 Sep; 281(37):27117-25. PubMed ID: 16849332
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin transiently up-regulates hHR23 expression through enhanced translational efficiency in A549 adenocarcinoma cells.
Shen YH; Chen BR; Cherng SH; Chueh PJ; Tan X; Lin YW; Lin JC; Chuang SM
Toxicol Lett; 2011 Sep; 205(3):341-50. PubMed ID: 21742020
[TBL] [Abstract][Full Text] [Related]
8. XPC is essential for nucleotide excision repair of zidovudine-induced DNA damage in human hepatoma cells.
Wu Q; Beland FA; Chang CW; Fang JL
Toxicol Appl Pharmacol; 2011 Mar; 251(2):155-62. PubMed ID: 21192964
[TBL] [Abstract][Full Text] [Related]
9. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
10. Expression of xeroderma pigmentosum complementation group C protein predicts cisplatin resistance in lung adenocarcinoma patients.
Lai TC; Chow KC; Fang HY; Cho HC; Chen CY; Lin TY; Chiang IP; Ho SP
Oncol Rep; 2011 May; 25(5):1243-51. PubMed ID: 21327329
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of cyclin A gene expression upon genotoxic stress correlates with reduced binding of free E2F to the promoter.
Spitkovsky D; Schulze A; Boye B; Jansen-Dürr P
Cell Growth Differ; 1997 Jun; 8(6):699-710. PubMed ID: 9186003
[TBL] [Abstract][Full Text] [Related]
12. Attenuated expression of xeroderma pigmentosum group C is associated with critical events in human bladder cancer carcinogenesis and progression.
Chen Z; Yang J; Wang G; Song B; Li J; Xu Z
Cancer Res; 2007 May; 67(10):4578-85. PubMed ID: 17510383
[TBL] [Abstract][Full Text] [Related]
13. XPC deficiency leads to centrosome amplification by inhibiting BRCA1 expression upon cisplatin-mediated DNA damage in human bladder cancer.
Wang H; Huang Y; Shi J; Zhi Y; Yuan F; Yu J; Chen Z; Yang J
Cancer Lett; 2019 Mar; 444():136-146. PubMed ID: 30579971
[TBL] [Abstract][Full Text] [Related]
14. p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene.
Adimoolam S; Ford JM
Proc Natl Acad Sci U S A; 2002 Oct; 99(20):12985-90. PubMed ID: 12242345
[TBL] [Abstract][Full Text] [Related]
15. Transcription abnormalities potentiate apoptosis of normal human fibroblasts.
Andera L; Wasylyk B
Mol Med; 1997 Dec; 3(12):852-63. PubMed ID: 9440118
[TBL] [Abstract][Full Text] [Related]
16. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents.
Fan S; el-Deiry WS; Bae I; Freeman J; Jondle D; Bhatia K; Fornace AJ; Magrath I; Kohn KW; O'Connor PM
Cancer Res; 1994 Nov; 54(22):5824-30. PubMed ID: 7954409
[TBL] [Abstract][Full Text] [Related]
17. Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin.
Kolfschoten GM; Hulscher TM; Schrier SM; van Houten VM; Pinedo HM; Boven E
Gynecol Oncol; 2002 Mar; 84(3):404-12. PubMed ID: 11855878
[TBL] [Abstract][Full Text] [Related]
18. Benzo(a)pyrene induces similar gene expression changes in testis of DNA repair proficient and deficient mice.
Verhofstad N; Pennings JL; van Oostrom CT; van Benthem J; van Schooten FJ; van Steeg H; Godschalk RW
BMC Genomics; 2010 May; 11():333. PubMed ID: 20504355
[TBL] [Abstract][Full Text] [Related]
19. A portrait of cisplatin-induced transcriptional changes in mouse embryonic stem cells reveals a dominant p53-like response.
Kruse JJ; Svensson JP; Huigsloot M; Giphart-Gassler M; Schoonen WG; Polman JE; Jean Horbach G; van de Water B; Vrieling H
Mutat Res; 2007 Apr; 617(1-2):58-70. PubMed ID: 17327130
[TBL] [Abstract][Full Text] [Related]
20. IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness.
Pavan S; Olivero M; Corà D; Di Renzo MF
Eur J Cancer; 2013 Mar; 49(4):964-73. PubMed ID: 23079474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
